跳至主要内容
临床试验/NCT03642223
NCT03642223已完成不适用

Relation Btw Adiposity, Inflammation & Iron Absorption:Comparison Btw Central & Peripheral Adiposity

Swiss Federal Institute of Technology1 个研究点 分布在 1 个国家目标入组 121 人开始时间: 2017年9月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
121
试验地点
1
主要终点
Fractional and total iron absorption

研究概览

简要总结

Adiposity is a state of sub-clinical inflammation, thus hepcidin is increased in adiposity, often leading to iron deficiency in this population group. Central adiposity is generally considered having a greater negative effect on health compared to peripheral adiposity. Whether this can be also seen in hepcidin and thereby in iron absorption is uncertain.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
20 Years 至 55 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • either normal-weight (BMI 18-25kg/m2) or overweight/obese (BMI 28-50kg/m2) with either central or peripheral fat deposits based on DEXA

排除标准

  • Iron Supplement or antibiotic intake within 2 weeks before study start
  • diagnosed chronic disease or gastrointestinal disorders
  • regular use of medication (except contraceptives)
  • pregnancy
  • lactation
  • blood donation or surgery within the last 4 months.

研究组 & 干预措施

central adiposity

Experimental

干预措施: Stable iron isotopes (Other)

peripheral adiposity

Experimental

干预措施: Stable iron isotopes (Other)

normal-weight

Active Comparator

干预措施: Stable iron isotopes (Other)

结局指标

主要结局

Fractional and total iron absorption

时间窗: 14days after the administration of the test meal

次要结局

  • Serum IL-6(at baseline)
  • Serum AGP(at baseline)
  • Serum Hepcidin(at baseline)
  • Serum ferritin(at baseline)
  • Serum TfR(at baseline)
  • Serum CRP(at baseline)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Prof. Michael B. Zimmermann

Prof. Dr. med.

Swiss Federal Institute of Technology

研究点 (1)

Loading locations...

相似试验